BioSpace News Archive

Eupraxia Pharmaceuticals Inc. announced that initial results from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week Annual Meeting 2024.

Instylla, Inc. today announced the completion of patient enrollment in the ongoing Instylla HES Hypervascular Tumor Pivotal Study.

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2024.

Anumana today announced the appointment of Harry S. Palmin as chief financial officer (CFO).

Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets.

XOMA Corporation, the biotech royalty aggregator, announced that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.

Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.

Xilio Therapeutics, Inc. announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2024.

Kura Oncology, Inc today announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company’s menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).